P14780 (MMP9_HUMAN) Homo sapiens (Human)

Matrix metalloproteinase-9 UniProtKBInterProSTRINGInteractive Modelling

707 aa; Sequence (Fasta)

Available Structures

29 Experimental Structures

DescriptionPDB IDOligo-stateRangeSeq id (%)Ligands
Structure determination of a potent, selective antibody inhibitor of human MMP9 (GS-5745 bound to M… Heteromer
40-443
100.0ZN;CA;NCO;
Crystal structure of mutant MMP-9 catalytic domain in complex with a twin inhibitor.homo-2-mer110-444
100ZN;CA;L29;
Crystal structure of an MMP twin carboxylate based inhibitor LC20 in complex with the MMP-9 catalyt…homo-2-mer110-444
100ZN;CA;0ZD;GOL;PGO;PEG;MLT;
MMP9 active site mutant-inhibitor complexhomo-2-mer110-443
100CA;STN;BUM;ZN;
Dimeric form of the haemopexin domain of MMP9homo-2-mer513-707
98.97SO4;
Crystal structure of human matrix metalloproteinase MMP9 (gelatinase B).monomer29-444
99.75ZN;CA;
Crystal structure of human proMMP-9 catalytic domain in complex with inhibitormonomer38-444
100ZN;CA;VP6;2HP;
Crystal structure of human proMMP-9 catalytic domain in complex with inhibitormonomer38-444
100.0ZN;CA;VOC;
Crystal structure of human proMMP-9 catalytic domain in complex with inhibitormonomer38-444
100.0ZN;CA;VOO;
Crystal structure of human proMMP-9 catalytic domain in complex with inhibitormonomer39-444
100.0ZN;CA;VOZ;
proMMP-9desFnII complexed to JNJ0966 INHIBITORmonomer40-443
100.0ZN;CA;SO4;
proMMP-9desFnIImonomer41-443
100ZN;CA;SO4;
Structure determination of a potent, selective antibody inhibitor of human MMP9 (apo MMP9)monomer41-443
100.0ZN;CA;
Crystal structure of an inactive mutant of MMP-9 catalytic domain in complex with a fluorogenic syn…monomer107-444
100AZI;ZN;CA;SR;PGO;EDO;PEG;GOL;
Crystal structure of an MMP broad spectrum hydroxamate based inhibitor CC27 in complex with the MMP…monomer107-444
100ZN;CA;10B;GOL;PGO;
Crystal structure MMP-9 complexes with a constrained hydroxamate based inhibitor LT4monomer107-444
100ZN;CA;LTQ;EDO;PGO;
Crystal structure of an inactive mutant of MMP-9 catalytic domain in complex with a fluorogenic syn…monomer107-444
100AZI;ZN;CA;SR;EDO;GOL;PGO;
Crystal structure of an MMP twin inhibitor complexing two MMP-9 catalytic domainsmonomer107-444
100ZN;CA;PEG;ACT;BCN;
Crystal structure of mutant MMP-9 catalytic domain in complex with a twin inhibitor.monomer110-444
100ZN;CA;0XX;
MMP-9 active site mutant with barbiturate inhibitormonomer110-443
100ZN;CA;CL;4MR;
MMP-9 active site mutant with phosphinate inhibitormonomer110-443
100ZN;CA;CL;5MR;
MMP-9 active site mutant with iodine-labeled carboxylate inhibitormonomer110-443
100ZN;CA;CL;6MR;
MMP-9 active site mutant with trifluoromethyl hydroxamate inhibitormonomer110-443
100ZN;CA;CL;7MR;
MMP9-inhibitor complexmonomer110-443
100CA;NFH;ZN;
Crystal structure of MMP9 in complex with inhibitor BE4.monomer112-444
100ZN;CA;B9Z;PZE;
Crystal structure of a hydroxamate based inhibitor EN140 in complex with the MMP-9 catalytic domainmonomer112-444
100E40;ZN;CA;EDO;PGO;PEG;
Crystal structure of a hydroxamate based inhibitor ARP101 (EN73) in complex with the MMP-9 catalyti…monomer113-444
100N73;ZN;CA;DMS;EDO;GOL;PGO;BUD;
Crystal structure of the catalytic domain of MMP-9 in complex with a selective sugar-conjugated ary…monomer113-444
100ZN;CA;H27;EDO;DMS;GOL;
MMP-9 active site mutant with difluoro butanoic acid inhibitormonomer113-443
100ZN;CA;CL;8MR;

2 SWISS-MODEL models

TemplateOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
1ck7.1.Amonomer0.6928-704
ZN;CA;48.47
1gxd.1.Amonomer0.53220-656
28.53